H.R. 9077: Hormone Health Data and Research Act

This bill, titled the Hormone Health Data and Research Act, aims to conduct scientific evaluations concerning hormone levels and testing during perimenopause in women. Here are the main components of the bill:

NIH Study

The Director of the National Institutes of Health (NIH) is tasked with reviewing existing evidence that relates to:

• The variability of hormone levels in women prior to experiencing symptoms of perimenopause.
• Identifying any baseline patterns in this variability.

U.S. Preventive Services Task Force Study

The Secretary of Health and Human Services, working through the U.S. Preventive Services Task Force (USPSTF), will analyze existing evidence regarding the effectiveness of hormone testing. This study will focus on whether establishing baseline hormone levels before symptoms of perimenopause can effectively guide the diagnosis or management of perimenopause in women.

Reporting Findings

Within 18 months of the bill's enactment, both the NIH and USPSTF are required to submit a comprehensive report to several Congressional committees, including the Committees on Appropriations and Energy and Commerce. This report will summarize their findings, identify any gaps in the available evidence, and offer recommendations for future research or clinical guidance on hormone health and perimenopause management.

Purpose

The overall goal of the bill is to enhance understanding of hormone variability in women undergoing perimenopause and the practicality of hormone testing, which could ultimately improve healthcare practices related to women's health during this transitional phase.

Relevant Companies

• ABT (Abbott Laboratories) - A company involved in medical testing and diagnostics, which may see changes in the demand for hormone testing products.
• RMD (ResMed Inc.) - Although primarily focused on respiratory products, they may expand into hormonal health diagnostics as market needs evolve.